No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
CHRS Coherus BioSciences
- 1.520
- +0.040+2.70%
Close Dec 20 16:00 ET
- 1.490
- -0.030-1.97%
Post 20:01 ET
175.12MMarket Cap-16.89P/E (TTM)
1.540High1.400Low4.30MVolume1.440Open1.480Pre Close6.44MTurnover4.16%Turnover RatioLossP/E (Static)115.21MShares3.70052wk High-1.99P/B157.01MFloat Cap0.66052wk Low--Dividend TTM103.30MShs Float38.100Historical High--Div YieldTTM9.46%Amplitude0.660Historical Low1.499Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer
Biosimilars Market Industry Trends and Global Forecasts to 2035, Featuring Amgen, BIOCAD, Biocon, Celltrion, Coherus BioSciences, Eli Lilly, Fresenius Kabi, Pfizer, Sandoz and Teva Pharmaceuticals - ResearchAndMarkets.com
TD Cowen Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)
Coherus BioSciences Price Target Raised to $6.00/Share From $4.00 by Baird
Coherus BioSciences Is Maintained at Outperform by Baird
Coherus Biosciences Announces Board Member Resignation
Heat List
US
Overall
Symbol
Price
% Chg
No Data